Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis
ConditionRhematoid Arthritis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-65
SponsorFoundation University Islamabad
About this trial
1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent. 2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled. 3. DNA will be extracted in the laboratory, and SNP will be identified. 4. The efficacy and toxicity data will be studied against the SNPs found 5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.
Eligibility criteria
Qualifiers
At baseline, all patients should fulfill the revised ACR/EULAR criteria for RA10
Pakistani individuals
between ages of 20-75 years
New cases started on Leflunomide/ those already taking for less than a month and their biochemical and clinical data is available
Disqualifiers
Patients not willing to participate/ consent not given
Patients below the age of 20
Non- Pakistani origin
Taking another DMARD simultaneously
Trial design
Treatments tested in this trial
- Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients
Treatment groups
110 Participants
are divided into 1 treatment groupSponsors and collaborators
Foundation University Islamabad
Lead sponsor
Shifa Tameer-e-Millat University
Collaborator
Source ClinicalTrials.gov